GEN Edge - Page 2 of 52 - GEN - Genetic Engineering and Biotechnology News

Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders

GEN Edge

Lilly’s GIP/GLP-1 Candidate Brenipatide Shows Early Clinical Promise in Substance, Psych Disorders

StockWatch: Novartis Loses More than Market Value After Phase III Failure

GEN Edge

StockWatch: Novartis Loses More than Market Value After Phase III Failure

Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial

GEN Edge

Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial

With $116M in Series A Financing, BrainChild Bio Targets CNS Tumors, Starting with One in Children’s Brainstems

Cancer

With $116M in Series A Financing, BrainChild Bio Targets CNS Tumors, Starting with One in Children’s Brainstems

Lilly Looks Beyond Obesity with Up-to-$2.9B Acquisition of Merida Biosciences

GEN Edge

Lilly Looks Beyond Obesity with Up-to-$2.9B Acquisition of Merida Biosciences

StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy

Cancer

StockWatch: Revolution Shares Stay Flat Despite Historic FDA Approval of Oral Pancreatic Cancer Therapy

Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer

Cancer

Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer

In Massachusetts, Latest Annual Snapshot Shows a Tale of Two Biopharmas

GEN Edge

In Massachusetts, Latest Annual Snapshot Shows a Tale of Two Biopharmas

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

Cancer

StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too

CDMOs Expand and Build for Future Growth

Bioprocessing

CDMOs Expand and Build for Future Growth